2 weeks Ago By ABMN Staff
Aclarion, Inc. ( NASDAQ:ACON – Get Free Report ) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 279,800 shares, a decrease of 6.
0% from the August 31st total of 297,700 shares. Based on an average trading volume of 575,200 shares, the short-interest ratio is presently 0.5 days.
Approximately 3.0% of the shares of the stock are short sold. Wall Street Analyst Weigh In Separately, Ascendiant Capital Markets reiterated a “buy” rating and set a $1.
50 price objective (down from $1.60) on shares of Aclarion in a research note on Monday, August 26th. Check Out Our Latest Stock Report on Aclarion Aclarion Price Performance Aclarion ( NASDAQ:ACON – Get Free Report ) last posted its earnings results on Wednesday, August 14th.
The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.
04. Aclarion had a negative net margin of 10,967.15% and a negative return on equity of 910.
84%. The company had revenue of $0.01 million during the quarter.
On average, research analysts predict that Aclarion will post -0.99 EPS for the current year. Institutional Trading of Aclarion An institutional investor recently bought a new position in Aclarion stock.
Virtu Financial LLC purchased a new position in shares of Aclarion, Inc. ( NASDAQ:ACON – Free Report ) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 115,183 shares of the company’s stock, valued at approximately $38,000.
Virtu Financial LLC owned approximately 1.40% of Aclarion as of its most recent SEC filing. Institutional investors and hedge funds own 7.
52% of the company’s stock. About Aclarion ( Get Free Report ) Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
See Also Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter ..
